Dark

Check out our API

ADVM
Adverum Biotechnologies, Inc. Common Stock
stock NASDAQ

Inactive

Dec 8, 2025

4.36USD+2.347%(+0.10)1,023,039

Pre-market

0.00USD-100.000%(-4.26)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 6, 2022

04:05PM EST Adverum Biotechnologies Appoints Star Seyedkazemi, Pharm.D. as GlobeNewswire Inc

Jan 4, 2022

08:04AM EST Adverum Biotechnologies Granted Orphan Drug Designation By FDA For Gene Therapy Candidate In Preclinical Development For Treatment Of Blue Cone Monochromacy Benzinga

08:00AM EST Adverum Biotechnologies Granted Orphan Drug Designation by FDA GlobeNewswire Inc

Dec 21, 2021

12:42PM EST Adverum Outlines Development Plan For ADVM-022 Gene Therapy In Wet AMD Benzinga

08:07AM EST Adverum Biotechnologies Says Finalizing 2-Dose Study Design For Phase 2 Trial Of ADVN-022 In Wet AMD With Intention To Dose First Patient In Q3 2022 Benzinga

08:00AM EST - Finalizing Two-Dose Study Design for Phase 2 Trial of ADVM-022 in Wet AMDwith Intention to Dose First Patient in Q32022 - GlobeNewswire Inc

Dec 6, 2021

09:08AM EST Adverum Biotechnologies Appoints Rupert D'Souza, Ph.D., M.B.A. As Chief Financial Officer Benzinga

09:00AM EST Adverum Biotechnologies Appoints Rupert DSouza, GlobeNewswire Inc

Nov 19, 2021

04:40PM EST Adverum Biotechnologies Inc On Nov 18, Co Informed Jack Thrift, Interim CFO, That His Role Will Cease In Near Term Benzinga

Nov 5, 2021

09:31AM EDT Adverum Biotechnologies Q3 EPS $(0.39) Down From $(0.31) YoY Benzinga

Oct 11, 2021

09:49AM EDT Adverum Biotech Saturday Morning Highlighted Will Present Data From Its INFINITY Trial Of ADVM-022 In Patients With Diabetic Macular Edema During American Society of Retina Specialists Meeting Oct. 11 At 9:50 a.m. EDT Benzinga

Oct 9, 2021

11:17AM EDT Adverum Presents Clinical Data on ADVM-022 at the American Society GlobeNewswire Inc

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Oct 4, 2021

02:32PM EDT Mid-Afternoon Market Update: Dow Drops 375 Points; Elmira Savings Bank Shares Spike Higher Benzinga

05:21AM EDT The following are some of the stocks making big moves in Monday's pre-market trading (as of 5.00 A.M. EDT). RTTNews

Oct 3, 2021

02:21PM EDT The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs and More Benzinga

Oct 1, 2021

04:03PM EDT Adverum Presents 2-Year OPTIC Data Demonstrating Sustained Durability And Promising Safety Profile From Single Intravitreal Injection Of ADVM-022 In Wet AMD Patients Who Previously Required Frequent Anti-VEGF Injections Benzinga

04:00PM EDT -- Results featured in a presentation today at the Retina Societys 54th Annual Scientific Meeting -- GlobeNewswire Inc

07:56AM EDT The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO Benzinga

Sep 27, 2021

09:05AM EDT Adverum To Present Data From ADVM-022 Clinical Trials At Upcoming Medical Conferences Benzinga

09:00AM EDT Adverum to Present Data from ADVM-022 Clinical Trials at Upcoming GlobeNewswire Inc

Aug 23, 2021

09:00AM EDT Adverum Appoints Global Regulatory Leader Jim Wang, Ph.D., as GlobeNewswire Inc

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 11, 2021

06:21AM EDT Adverum Biotech 8-K Shows Acting CFO, Christopher DeRespino, To Resign; Co. Is Engaged In Ongoing Search For New CFO Benzinga

Aug 5, 2021

04:45PM EDT Adverum Biotechnologies Q2 EPS $(0.45) Down From $(0.36) YoY Benzinga

Aug 3, 2021

07:55AM EDT The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business Benzinga

Jul 23, 2021

02:58PM EDT Where Adverum Biotechnologies Stands With Analysts Benzinga

10:24AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 23, 2021 Benzinga

08:46AM EDT Chardan Capital Maintains Neutral on Adverum Biotechnologies, Lowers Price Target to $3 Benzinga

07:59AM EDT 10 Biggest Price Target Changes For Friday Benzinga

07:45AM EDT The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs Benzinga

06:31AM EDT Cantor Fitzgerald Downgrades Adverum Biotechnologies to Neutral, Lowers Price Target to $3 Benzinga

06:08AM EDT Adverum Stock Falls As It Stops Testing Ocular Gene Therapy Candidate In Diabetic Macular Edema Patients Benzinga

04:38AM EDT SVB Leerink Maintains Market Perform on Adverum Biotechnologies, Lowers Price Target to $2 Benzinga

Jul 22, 2021

04:09PM EDT Adverum Shares To Resume Trade At 4:35 p.m EDT Benzinga

04:09PM EDT Adverum Biotech Revises Plan For Development Of ADVM-022 To Focus On Wet AMD, Low Doses; Says Will No Longer Develop Candidate For Indication Of Diabetic Macular Edema Benzinga

04:05PM EDT -- Based on latest analyses, company is revising ADVM-022 development plan to focus onwet AMD and low doses (2 x 10^11 vg/eye and lower);no longer planning development for DME -- GlobeNewswire Inc

04:03PM EDT Adverum Biotechnologies Shares Halted On Code News Pending Benzinga

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 15, 2021

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 8, 2021

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

Jul 1, 2021

08:11AM EDT Adverum Biotechnologies Appoints Jon Williams VP, Clinical Affairs RTTNews

08:00AM EDT Adverum Announces Appointment of Jon Williams, Ph.D., GlobeNewswire Inc

Jun 24, 2021

04:08PM EDT Adverum Announces Christopher J. DeRespino Appointed Acting CFO, Peter Soparkar Appointed COO Benzinga

04:05PM EDT -- Christopher J. DeRespino appointed acting CFO -- GlobeNewswire Inc

Jun 1, 2021

08:00AM EDT -- Julie Clark, M.D., appointed chief medical officer -- GlobeNewswire Inc

May 25, 2021

07:53AM EDT The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal Benzinga

May 20, 2021

08:27AM EDT The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks Benzinga

May 12, 2021

03:17PM EDT The Sonic Fund II, L.P. Comments on Preliminary Voting Results of Adverum Annual Meeting Business Wire

01:08PM EDT Adverum Stockholders Re-Elect All Adverum Director Nominees At 2021 Annual Meeting Benzinga

01:05PM EDT Adverum Stockholders Re-Elect All Adverum Director Nominees at GlobeNewswire Inc

May 11, 2021

03:16PM EDT The Sonic Fund II, L.P. Issues Statement To Adverum Stockholders (Full Statement) Benzinga

03:15PM EDT The Sonic Fund II, L.P. Issues Statement to Adverum Stockholders Business Wire

May 10, 2021

10:41AM EDT The Sonic Fund II, L.P. Reminds Adverum Stockholders to Vote for Its Three Independent Director Nominees at May 12 Annual Meeting Business Wire

08:15AM EDT Adverum Biotechnologies Inc. (Adverum) (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today issued the following statement regarding the Annual Meeting of Stockholders (Annual Meeting) scheduled for May 12, 2021: GlobeNewswire Inc

May 6, 2021

04:03PM EDT Adverum Biotechnologies Q1 EPS $(0.29) Up From $(0.31) YoY, Sales $7.50M Benzinga

04:00PM EDT Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the first quarter ended March 31, 2021. GlobeNewswire Inc

09:53AM EDT Glass Lewis Joins ISS In Recommending Adverum Shareholders Vote For All Three Independent Sonic Director Nominees RTTNews

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

May 5, 2021

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

May 4, 2021

08:39AM EDT Adverum Biotech Shareholder, The Sonic Fund II, Reports ISS Recommended Co. Shareholders Vote To Elect Firm's 3 Independent Director Nominees Benzinga

08:30AM EDT ISS Recommends Adverum Stockholders Vote to Elect Sonic's Three Independent, Highly Qualified Nominees Business Wire

08:10AM EDT The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data Benzinga

May 3, 2021

02:59PM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2021 Benzinga

09:46AM EDT Adverum Biotechnologies shares were trading higher after the company announced new long-term data from the OPTIC clinical trial of ADVM-022 single intravitreal injection gene therapy in treatment-experienced wet AMD patients at ARVO 2021. Benzinga

07:47AM EDT SVB Leerink Downgrades Adverum Biotechnologies to Market Perform, Announces $5 Price Target Benzinga

06:08AM EDT Adverum's Wet AMD Gene Therapy Shows Long Term Benefit In Treatment-Experienced Patients Benzinga

May 1, 2021

03:26PM EDT -- Long-term durability and maintained efficacy; sustained robust aflibercept protein expression observed -- GlobeNewswire Inc

Apr 30, 2021

07:31AM EDT The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs Benzinga

Apr 29, 2021

02:58PM EDT The Sonic Fund II, L.P. Comments on Adverum Biotechnologies Update Regarding INFINITY Phase 2 Trial of ADVM-022 Business Wire

02:30PM EDT Mid-Afternoon Market Update: Dow Gains 175 Points; JAKKS Pacific Shares Climb After Q1 Results Benzinga

12:47PM EDT Mid-Day Market Update: Nasdaq Turns Lower; Galera Therapeutics Shares Surge Benzinga

12:12PM EDT Chardan Capital Downgrades Adverum Biotechnologies to Neutral, Lowers Price Target to $5 Benzinga

10:32AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 29, 2021 Benzinga

10:24AM EDT Mid-Morning Market Update: Markets Open Higher; McDonald's Profit Beats Estimates Benzinga

09:01AM EDT Truist Securities Downgrades Adverum Biotechnologies to Hold, Lowers Price Target to $9 Benzinga

08:15AM EDT The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx Benzinga

06:58AM EDT RBC Capital Downgrades Adverum Biotechnologies to Sector Perform, Announces $6 Price Target Benzinga

06:12AM EDT SVB Leerink Maintains Outperform on Adverum Biotechnologies, Lowers Price Target to $11 Benzinga

05:32AM EDT Adverum's Stock Crashes After DME Gene Therapy Trial Derails On One Patient's Serious Adverse Event Benzinga

Apr 28, 2021

04:04PM EDT Adverum Biotechnologies Shares Set To Resume Trading At 4:30 p.m. EST Benzinga

04:03PM EDT Adverum Biotechnologies Provides Update On INFINITY Trial Evaluating ADVM-022 In Patients With Diabetic Macular Edema; Co Says Has Decided To Immediately Unmask INFINITY Phase 2 Study Benzinga

04:03PM EDT Adverum Biotechnologies Shares Halted On Code News Pending Benzinga

04:01PM EDT AdverumBiotechnologies Provides Update on the INFINITY GlobeNewswire Inc

Apr 26, 2021

09:00AM EDT The Sonic Fund II, L.P. Issues Presentation Correcting Adverum's Misstatements Business Wire

Apr 22, 2021

05:00PM EDT The Sonic Fund II, L.P. Issues Presentation Detailing Compelling Case for Immediate Board Upgrade at Adverum Biotechnologies, Inc. Business Wire

04:15PM EDT Urges Stockholders to Vote the WHITE Proxy Card FOR ALL of Adverums Three Highly Qualified, Diverse and Independent Directors: Dawn Svoronos, Reed V. Tuckson, M.D. and Thomas Woiwode, Ph.D. GlobeNewswire Inc

Apr 21, 2021

08:00AM EDT Sonics Nominees Lack Experience and Qualifications to Advance Adverums Commercialization Progress or Deliver Global Access to Vision-Saving Gene Therapy GlobeNewswire Inc

Apr 19, 2021

04:10PM EDT The Sonic Fund II, L.P. Files Definitive Proxy Statement and Sends Letter to Stockholders of Adverum Biotechnologies, Inc. Business Wire

Apr 16, 2021

08:08AM EDT Adverum Biotechnologies To Present New Data From OPTIC Trial Of ADVM-022 Intravitreal Gene Therapy For Wet AMD At Association For Research In Vision And Ophthalmology 2021 On May 3 Benzinga

08:05AM EDT -- Adverum to host webcast with key opinion leaders onSunday, May 2, 2021 at 7:00 AM PT-- GlobeNewswire Inc

Apr 15, 2021

08:00AM EDT Urges Stockholders to Vote the WHITEProxy Card FOR ALL of Adverums Three Highly Qualified, Diverse and Independent Directors: Dawn Svoronos, Reed Tuckson, M.D. and Tom Woiwode, Ph.D. GlobeNewswire Inc

Apr 14, 2021

07:51AM EDT The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead Benzinga

Apr 13, 2021

08:16AM EDT The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug Benzinga

Apr 8, 2021

09:40AM EDT Election of Highly Qualified Independent Directors at the 2021 Annual Meeting of Adverum Biotechnologies, Inc. PR Newswire

Mar 30, 2021

09:05AM EDT Adverum Announces Senior Appointments For Patient Access And Clinical Operations As ADVM-022 Advances Toward Global Phase 3 Trials Benzinga

09:00AM EDT -- Anand Reddi appointed vice president, patient advocacy, access, anddigital innovation -- GlobeNewswire Inc

Mar 18, 2021

04:00PM EDT Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc

02:31PM EDT The Sonic Fund Reports In 13D Filing A 6.2% Stake In Adverum Biotechnologies Benzinga

08:16AM EDT The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq Benzinga

Mar 17, 2021

05:10PM EDT Adverum Announces Board Slate for 2021 Annual Meeting and GlobeNewswire Inc

Mar 1, 2021

04:01PM EST Adverum Biotechnologies Q4 EPS $(0.39) Misses $(0.32) Estimate Benzinga

04:00PM EST Adverum Announces Shortened Timelines and Clear Development Path GlobeNewswire Inc

03:51AM EST Earnings Scheduled For March 1, 2021 Benzinga

Feb 27, 2021

09:04PM EST The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings Benzinga

Feb 22, 2021

04:00PM EST Adverum to Host Conference Call and Webcast to Highlight Updated GlobeNewswire Inc

09:00AM EST Adverum Appoints Esteemed Healthcare Executive Reed V. Tuckson, GlobeNewswire Inc

Feb 18, 2021

04:00PM EST Adverum Appoints Christopher J. DeRespino as Chief Business Officer GlobeNewswire Inc

Feb 10, 2021

04:51PM EST Adverum Announces That It Will Present Data For Its OPTIC Phase 1 Trial With ADVM-022 Intravitreal Gene Therapy In Wet AMD At The Angiogenesis Exudation And Degeneration Meeting Benzinga

04:49PM EST Adverum to Present Data from the OPTIC Phase 1 Trial with ADVM-022 GlobeNewswire Inc

Feb 2, 2021

09:06AM EST Adverum Biotech Highlights Publication Of Preclinical Long-Term Safety Data On ADVM-022 IVT Gene Therapy Benzinga

09:00AM EST Adverum Biotechnologies Announces Publication of Preclinical GlobeNewswire Inc

Jan 24, 2021

07:12AM EST Notable Insider Buys Of The Past Week: Affirm, HEICO, Vector Group, Biotechs And More Benzinga

Jan 11, 2021

08:11AM EST Adverum Biotechnologies Completes Patient Enrollment For INFINITY Phase 2 Trial Of ADVM-022 In DME Benzinga

08:00AM EST Adverum Biotechnologies Completes Patient Enrollment for INFINITY GlobeNewswire Inc

Jan 7, 2021

12:01PM EST Adverum Biotechnologies Announces New GMP Gene Therapy Manufacturing Facility Benzinga

11:57AM EST -- 174,000-square-foot commercial GMP facility in Durham, NC for the manufacturing of ADVM-022, an intravitreal gene therapy in development for wet AMD and DME -- GlobeNewswire Inc

Jan 5, 2021

09:00AM EST Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the companys presentation at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 10:50 a.m. ET. GlobeNewswire Inc

Dec 17, 2020

05:17PM EST Adverum Biotechnologies Files Prospectus Supplement Related To Common Stock Offering Of Up To $150M Benzinga

Dec 14, 2020

09:00AM EST Adverum Biotechnologies Appoints Pharmaceutical Industry Veteran GlobeNewswire Inc

Nov 23, 2020

11:00AM EST Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the companys presentation at the Piper Sandler 32nd Annual Virtual Healthcare Conference. GlobeNewswire Inc

Nov 14, 2020

10:08AM EST Adverum Biotechnologies Announced Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD Benzinga

10:00AM EST -- Maintained efficacy and greatly reduced anti-VEGF treatment burden aftera single IVT injection of ADVM-022 -- GlobeNewswire Inc

Nov 13, 2020

07:40AM EST The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 5, 2020

04:34PM EST Adverum Biotechnologies Q3 EPS $(0.31) Down From $(0.25) YoY Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Oct 20, 2020

09:03AM EDT Adverum Biotechnologies To Present New Data From OPTIC Phase 1 Trial Of ADVM-022 Intravitreal Gene Therapy For Wet AMD At AAO 2020 Virtual Benzinga

09:00AM EDT -- Dr. Carl Regillo to present OPTIC data at the Retina Subspecialty Day onFriday, November 13, 2020 at 2:15 pm PT -- GlobeNewswire Inc

Sep 15, 2020

08:00AM EDT Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Christopher J. Morrison, Ph.D. joined the company as vice president, process development, reporting into Adverums chief technology officer Angela Thedinga. GlobeNewswire Inc

Sep 10, 2020

08:00AM EDT Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the company will present at the Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020 at 1:00 pm PT. GlobeNewswire Inc

Aug 18, 2020

09:00AM EDT Adverum Biotechnologies Announces Closing of $217 GlobeNewswire Inc

Aug 12, 2020

09:38PM EDT Adverum Biotechnologies Announces Pricing of Public Offering of GlobeNewswire Inc

Aug 11, 2020

04:15PM EDT Adverum Biotechnologies Announces A $200M Common Stock offering Benzinga

04:05PM EDT Adverum Biotechnologies Announces $200M Public Offering Of Common Stock Benzinga

04:01PM EDT Adverum Biotechnologies Announces $200 Million Public Offering of GlobeNewswire Inc

06:48AM EDT SVB Leerink Maintains Outperform on Adverum Biotechnologies, Raises Price Target to $21 Benzinga

Aug 10, 2020

04:01PM EDT Adverum Biotechnologies Q2 EPS $(0.36) Misses $(0.28) Estimate Benzinga

04:01PM EDT Adverum Biotechnologies Announces Interim Data From Cohorts 1-4 From OPTIC Phase 1 Trial Of ADVM-022 Intravitreal Gene Therapy For wet AMD Benzinga

04:00PM EDT -- Continued robust treatment response from both high and low doses -- GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For August 10, 2020 Benzinga

Jul 29, 2020

04:05PM EDT Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it will host a conference call and webcast on Monday, August 10, 2020 at 1:30 pm PT/4:30 pm ET to report its second quarter 2020 financial results and provide a corporate update. GlobeNewswire Inc

Jul 21, 2020

08:01AM EDT Adverum Biotechnologies Announces Appointment of Thomas Kochy as GlobeNewswire Inc

Jul 13, 2020

08:31AM EDT Adverum Biotechnologies Announces First Patient Randomized In Phase 2 INFINITY Trial Of ADVM-022 Single Injection Gene Therapy For Diabetic Macular Edema Benzinga

08:30AM EDT -- INFINITY trial is currently enrolling patients with DME, the most common cause of vision loss in people with diabetic retinopathy -- GlobeNewswire Inc

Share